Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy, Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy, Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?, Rational Design of adjuvants boosts cancer vaccines, Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma.
Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Contributors - p. xi 7. Preface - p. xiii 8. Chapter One: Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment - p. 1 9. Chapter Two: Breakthroughs in synthetic controlling strategies for precision in CAR-T therapy - p. 61 10. Chapter Three: Rational design of adjuvants boosts cancer vaccines - p. 101 11. Chapter Four: The promise, progress, and challenges of in situ immunization agents in cancer immunotherapy - p. 127 12. Chapter Five: Emerging drug delivery systems to alter tumor immunosuppressive microenvironment: Overcoming the challenges in immunotherapy for glioblastoma - p. 165 13. Chapter Six: Magnetic nanoparticles: An emerging nanomedicine for cancer immunotherapy - p. 183 14. Chapter Seven: Non-coding RNAs in cancer immunotherapy: A solution to overcome immune resistance? - p. 215 15. Chapter Eight: Immunotherapy outcomes in non-small cell lung cancer according to a gender perspective - p. 241 16. Index - p. 259
Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy, Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy, Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?, Rational Design of adjuvants boosts cancer vaccines, Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma.
Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Contributors - p. xi 7. Preface - p. xiii 8. Chapter One: Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment - p. 1 9. Chapter Two: Breakthroughs in synthetic controlling strategies for precision in CAR-T therapy - p. 61 10. Chapter Three: Rational design of adjuvants boosts cancer vaccines - p. 101 11. Chapter Four: The promise, progress, and challenges of in situ immunization agents in cancer immunotherapy - p. 127 12. Chapter Five: Emerging drug delivery systems to alter tumor immunosuppressive microenvironment: Overcoming the challenges in immunotherapy for glioblastoma - p. 165 13. Chapter Six: Magnetic nanoparticles: An emerging nanomedicine for cancer immunotherapy - p. 183 14. Chapter Seven: Non-coding RNAs in cancer immunotherapy: A solution to overcome immune resistance? - p. 215 15. Chapter Eight: Immunotherapy outcomes in non-small cell lung cancer according to a gender perspective - p. 241 16. Index - p. 259
